Financial News · Live Terminal

Page 576 of 692

Truist Raises Price Target on Glaukos to $160 From $145, Keeps Buy Rating

Glaukos (GKOS) has an average rating of buy and mean price target of $149 according to analysts polled by FactSet.Price: $135.34, Change: $+18.38, Percent Change: +15.71%

$GKOS

Wire146d ago

Inspira, Qarakal Partner on Cryogenic Connectivity for Quantum Systems

Inspira Technologies (IINN) said Thursday it entered a joint development agreement with Qarakal Quantum to test cryogenic interconnect technologies for superconducting quantum systems.The collaboration will evaluate Inspira's additively manufactured electronics platform in quantum-relevant cryogenic conditions, with Qarakal providing technical requirements and conducting integration and testing at milli-Kelvin temperatures.Shares of Inspira were up 3.6% in Thursday trading.Price: $0.46, Change: $+0.02, Percent Change: +3.56%

$IINN

Wire146d ago

Mizuho Raises Price Target on Air Products & Chemicals to $345 From $330, Keeps Outperform Rating

Air Products & Chemicals (APD) has an average rating of overweight and mean price target of $324.68 according to analysts polled by FactSet.Price: $299.49, Change: $-3.01, Percent Change: -1.00%

$APD

Wire146d ago

Oppenheimer Adjusts Price Target on Equinix to $1,200 From $975, Maintains Outperform Rating

Equinix (EQIX) has an average rating of overweight and mean price target of $1,185.67, according to analysts polled by FactSet.Price: $1055.80, Change: $-33.27, Percent Change: -3.05%

$EQIX

Wire146d ago

Stephens Adjusts Price Target on Vulcan Materials to $340 From $330

Vulcan Materials Company (VMC) has an average rating of overweight and mean price target of $334.50, according to analysts polled by FactSet.Price: $299.90, Change: $+3.82, Percent Change: +1.29%

$VMC

Wire146d ago

Wedbush Cuts Price Target on Rithm Capital to $12.50 From $14, Keeps Outperform Rating

Rithm Capital (RITM) has an average rating of buy and mean price target of $13.65 according to analysts polled by FactSet.Price: $9.84, Change: $+0.18, Percent Change: +1.86%

$RITM

Wire146d ago

Accenture Invests in Customer Experience Agentic AI Platform Netomi

Accenture (ACN) has invested in Netomi, a customer experience artificial intelligence platform, through its Accenture Ventures arm, the company said Thursday.No financial terms were disclosed.The investment is expected to expand Accenture's customer experience and service capabilities through the integration of Netomi's agentic AI platform, the company said.Netomi said in a separate statement that it raised $110 million in new funding led by Accenture Ventures, with participation from Adobe Ventures, WndrCo, SLW, NAVER Ventures, Metis Strategy, and Fin Capital.Price: $176.25, Change: $-4.01, Percent Change: -2.22%

$ACN

Wire146d ago

Barclays Adjusts Price Target on Vulcan Materials to $340 From $296

Vulcan Materials Company (VMC) has an average rating of overweight and mean price target of $334.50, according to analysts polled by FactSet.Price: $300.20, Change: $+4.12, Percent Change: +1.39%

$VMC

Wire146d ago

New Street Research Lowers Microsoft Price Target to $600 From $675, Maintains Buy Rating

Microsoft (MSFT) has an average rating of Buy and mean price target of $562.51, according to analysts polled by FactSet.Price: $403.13, Change: $-21.33, Percent Change: -5.03%

$MSFT

Wire146d ago

Oppenheimer Adjusts Price Target on Amazon.com to $320 From $275, Maintains Outperform Rating

Amazon.com (AMZN) has an average rating of buy and mean price target of $300.15, according to analysts polled by FactSet.Price: $259.34, Change: $-3.70, Percent Change: -1.41%

$AMZN

Wire146d ago

Corning Keeps Quarterly Dividend at $0.28 per Share, Payable June 29 to Holders of Record May 29

$GLW

Wire146d ago

Zephirin Cuts Price Target on NOV to $17 From $18, Keeps Hold Rating, Medium Risk

NOV (NOV) has an average rating of hold and mean price target of $21.58 according to analysts polled by FactSet.Price: $20.60, Change: $-0.16, Percent Change: -0.77%

$NOV

Wire146d ago

Satellogic Signs $12 Million Deal for In-Orbit NewSat Satellite Delivery

Satellogic (SATL) said Thursday it has signed a $12 million agreement with an unnamed sovereign defense customer to deliver a commissioned, in-orbit NewSat satellite from its operational Aleph-1 constellation.The company said the deal transfers full ownership and operational control of the satellite to the customer and that it will also provide technical support to help the customer independently command the craft and process data for military and civilian use.Satellogic said the transfer process will begin immediately and is expected to be completed in early 2027, subject to contractual and regulatory milestones.Shares of Satellogic were up 6.4% in Thursday trading.Price: $6.55, Change: $+0.40, Percent Change: +6.42%

$SATL

Wire146d ago

AMETEK to Buy First Aviation Services

AMETEK (AME) said Thursday it has agreed to acquire First Aviation Services, which provides defense and aviation maintenance, repair and overhaul services and also makes related parts.First Aviation has annual sales of about $80 million and operates six centers in the US, AMETEK said, adding the deal is subject to closing conditions, including regulatory clearance.AMETEK shares were up 3.5% in Thursday morning trading.Price: $236.36, Change: $+8.49, Percent Change: +3.73%

$AME

Wire146d ago

Orchestra BioMed Gets Second FDA Breakthrough Designation for Hypertension Therapy

Orchestra BioMed (OBIO) said Thursday the US Food and Drug Administration granted a second Breakthrough Device designation for its atrioventricular interval modulation therapy.The designation covers patients with uncontrolled hypertension despite the use of antihypertensive medications, including those who are indicated for a pacemaker.Orchestra BioMed has a collaboration with Medtronic (MDT) to develop and commercialize the therapy for pacemaker-indicated patients, according to the statement.Price: $3.79, Change: $-0.01, Percent Change: -0.21%

$MDT$OBIO

Wire146d ago

Acadian Asset Management Shares Increase After Q1 Adjusted Earnings, Revenue Rise

Acadian Asset Management (AAMI) shares rose 5% in Thursday trading after it reported Q1 adjusted earnings of $1.05 per share, up from $0.54 a year earlier.Two analysts surveyed by FactSet expected $0.82.Revenue for the quarter ended March 31 was $167 million, up from $119.9 million a year earlier.Analysts polled by FactSet expected $154 million.The company's board maintained a quarterly dividend of $0.10 per share, payable June 26 to shareholders of record as of June 12.Price: $67.38, Change: $+2.30, Percent Change: +3.53%

$AAMI

Wire146d ago

Wedbush Lowers Price Target on Tenable Holdings to $27 From $32, Keeps Outperform Rating

Tenable Holdings (TENB) has an average rating of overweight and mean price target of $28 according to analysts polled by FactSet.Price: $20.42, Change: $-1.05, Percent Change: -4.89%

$TENB

Wire146d ago

UBS Adjusts Scotts Miracle-Gro Price Target to $70 From $67, Maintains Neutral Rating

Scotts Miracle-Gro (SMG) has an average rating of overweight and mean price target of $74, according to analysts polled by FactSet.Price: $60.20, Change: $-2.22, Percent Change: -3.56%

$SMG

Wire146d ago

UBS Adjusts Viavi Solutions Price Target to $60 From $25, Maintains Neutral Rating

$VIAV

Wire146d ago

Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer

Telomir Pharmaceuticals (TELO) said Thursday the US Food and Drug Administration has approved its investigational new drug application for its lead candidate Telomir-Zn to treat people with advanced or metastatic triple-negative breast cancer.The clearance will allow the company to advance Telomir-Zn into clinical evaluation, Telomir said, adding it plans to start the first-in-human phase 1/2 trial in H1.Telomir shares were down over 2% in Thursday morning trading.Price: $1.43, Change: $-0.02, Percent Change: -1.38%

$TELO

Showing 11501-11520 of 13824